Background: Bariatric surgery is the most effective treatment for morbid obesity, resulting in sustained weight loss as well as pronounced beneficial effects on obesityrelated comorbidities. However, postoperative venous thromboembolism (VTE) remains a leading cause of morbidity and mortality post Laparoscopic Sleeve Gastrectomy (LSG).
Objective: To evaluate inpatient and outpatient VTE prophylaxis prescribing trends in relation to VTE and bleeding outcomes post LSG.
Setting: Two academic medical centers.
Method: Retrospective chart review was performed of all adult patients who underwent primary LSG at two academic medical centers between May 30, 2015 and April 30, 2017.
Results: Majority of patients received perioperative VTE prophylaxis with unfractionated heparin (UFH) and was continued throughout hospital admission. On discharge, only 9% of patients were prescribed VTE chemoprophylaxis. Based on a regression analysis, a Body Mass Index (BMI) of greater than or equal to 50 kg/m2 (odds ratio [95%CI], 59.44 [27.6-127.9]) and a history of VTE (odds ratio [95%CI], 18.0 [5.35-60.36]) demonstrated a trend towards physicians prescribing VTE prophylaxis more at discharge. Rates of VTE and bleeding were low (0.5% and 0.8% respectively).
Conclusion: Chemoprophylaxis for high risk patients, such as those with BMI greater than or equal to 50 kg/m2 or a history of VTE event, may be considered for a 28-day regimen of therapy.
Journal of Pharmacy Practice and Education received 42 citations as per Google Scholar report